Protocol Ledger

NCT04445272 · Phase II · COMPLETED

Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia

Interventional Phase II clinical trial protocol NCT04445272 sponsored by Fundacion SEIMC-GESIDA in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-22 Enrollment: 495 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04445272
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)495 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04445272
Protocol FieldVerified Registry Value
NCT IdentifierNCT04445272
Consolidated Lead SponsorFundacion SEIMC-GESIDA
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment495 participants (ACTUAL)
Registered Start Date2020-05-22
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI